Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled date : 2022 - 02 - 28 save search
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -0.81%
H: 3.12%
C: 2.96%
covid-19 trial covid disease vaccine infection phase 3 infections
Acasti Pharma Celebrates Rare Disease Day
Published: 2022-02-28 (Crawled : 20:00) - biospace.com/
ACST | $3.07 -3.91% 20K
|
Health Technology
|
| O: -2.65%
H: 4.54%
C: 1.82%
day rare disease cel pharma
Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease
Published: 2022-02-28 (Crawled : 15:00) - travere.com
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: 1.08%
H: 3.98%
C: 0.44%
day rare therapeutics disease
AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
Published: 2022-02-28 (Crawled : 14:30) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
imbruvica disease
Applied Therapeutics Supports 15th Annual Rare Disease Day
Published: 2022-02-28 (Crawled : 13:00) - appliedtherapeutics.com
APLT A | $4.4 -7.17% -7.73% 2.9M
|
Health Technology
|
| O: 0.5%
H: 0.5%
C: -6.0%
day rare therapeutics disease
Janssen is Taking a Big Swing at Autoantibody-Driven Diseases
Published: 2022-02-28 (Crawled : 06:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
disease antibody
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.